Disha Narang, an endocrinologist and the director of Obesity Medicine at Northwestern Lake Forest Hospital in Illinois, told The Post compounded semaglutide is not FDA approved and we dont have any data on long-term efficacy. Furthermore, she said Eli Lilly and Novo Nordisk, the makers of diabetes drugs tirzepatide and semaglutide, are going to be coming after a lot of these manufacturers that are making compounded substances. In a press release distributed last week, Novo Nordisk cited trademark issues and safety concerns and said it is taking steps to protect US patients from the unlawful marketing and sales of non-FDA approved counterfeit and compounded semaglutide products claiming to contain semaglutide, while reinforcing the responsible use of Novo Nordisks FDA-approved medicines. Novo Nordisk has commenced the filing of legal actions in the US against certain medical spas, weight loss or wellness clinics, and compounding pharmacies to cease and desist from false advertising, trademark infringement and/or unlawful sales of non-FDA approved compounded products claiming to contain semaglutide, said the release
[4] Physical reactions After stopping Ozempic, the following physical effects can occur: [2][3][4][5] Weight is regained: Ozempic reduces appetite, and once the medication is stopped, appetite will likely return to normal, potentially leading to an increase in food intake and weight gain
Retatrutide will be a new medication for diabetes, weight loss and may also show promising cardiovascular benefits
Comparisons among different groups were followed using Tukey post hoc analysis
